Table 1 Characteristics of the included studies
Author | Country | Design | MOA | Cell dose | Stroke type | Day of the Procedurea | No. of patients | Gender (M/F) | Age | NOS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
I | C | I | C | I | C | ||||||||
Bang et al. [17] | South Korea | RCT | IV | 50 × 106 twice | IS | 7 | 5 | 25 | 4/1 | 14/11 | 63.0 ± 7.5 | 59.3 ± 11.5 | NA |
Lee et al. [18] | South Korea | RCT | IV | 5 × 107 | IS | 7 | 16 | 36 | 8/8 | 26/10 | 64.9 ± 14.5 | 64.0 ± 11.6 | NA |
Moniche et al. [25] | Spain | Non-RCT | IA | NA | IS | 5–9 | 10 | 10 | 5/5 | 7/3 | 66.9 ± 13.9 | 67.4 ± 12.7 | 7 |
Bhasin et al. [19] | India | Non-RCT | IV | 50-60 × 106 | IS & ICH | 23 | 20 | 20 | 18/2 | 17/3 | 45.1 ± 12.1 | 45.2 ± 11.8 | 6 |
Li et al. [22] | China | Non-RCT | IC | 9.47 × 105 | ICH | 5–7 | 60 | 40 | 37/23 | 23/17 | 56.3 ± 2.9 | 55.9 ± 4.7 | 6 |
Prasad et al. [20] | India | RCT | IV | 268 × 106 | Subacute IS | NA | 60 | 60 | 41/19 | 36/24 | 50.7 ± 11.6 | 52.5 ± 12.1 | NA |
Ghali et al. [23] | Egypt | Non-RCT | IA | 1 × 106 | Subacute IS | 22 | 21 | 18 | 12/9 | 10/8 | 55.5 ± 5.3 | 56.25 ± 4.5 | 6 |
Bhatia et al. [21] | India | RCT | IA | 6.1 × 108 | Subacute IS | 7 | 10 | 10 | 6/4 | 8/2 | 57 ± 12.2 | 66.0 ± 7.3 | NA |
Savitz et al. [24] | USA | RCT | IA | 3.08 × 106 | IS | 11–17 | 29 | 19 | 20/9 | 15/4 | 59.3 ± 10.03 | 62.9 ± 10.81 | NA |